Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX)

CUSIP: 22053A107

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class
Equity / Common Stock, par value $0.0001 par value
Shares outstanding
55,541,178
Total 13F shares
11,792,663
Share change
+4,213,853
Total reported value
$19,221,893
Price per share
$1.63
Number of holders
45
Value change
+$6,863,019
Number of buys
21
Number of sells
13

Quarterly Holders Quick Answers

What is CUSIP 22053A107?
CUSIP 22053A107 identifies QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX) as of Q3 2025

As of 30 Sep 2025, Quince Therapeutics, Inc. - Common Stock, par value $0.0001 par value (QNCX) was held by 45 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 11,792,663 shares. The largest 10 holders included Nantahala Capital Management, LLC, VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, IEQ CAPITAL, LLC, ADAR1 Capital Management, LLC, Almitas Capital LLC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock, Inc., and HighTower Advisors, LLC. This page lists 45 institutional shareholders reporting positions in this security for the Q3 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.